A multifactor epidemiological analysis of risk factors for pancreatic cancer in women
Authors:
K. Azeem 1; D. Horáková 1; H. Tomášková 2; J. Ševčíková 1; J. Vlčková 1; D. Pastucha 3; V. Procházka 4; O. Shonová 5; A. Martínek 6; V. Janout 1; V. Žídková 1; H. Kollárová 1
Authors‘ workplace:
Ústav preventivního lékařství, LF Univerzity Palackého v Olomouci
1; Ústav epidemiologie a ochrany veřejného zdraví, LF OU v Ostravě
2; Ústav rehabilitace LF, OU v Ostravě
3; II. interní klinika – gastro-enterologická a hepatologická, FN Olomouc
4; Gastroenterologické oddělení, Nemocnice České Budějovice, a. s.
5; Interní klinika FN Ostrava
6
Published in:
Epidemiol. Mikrobiol. Imunol. 64, 2015, č. 1, s. 34-40
Category:
Review articles, original papers, case report
Overview
Study objective:
A multifactor analysis of risk factors for pancreas cancer in women.
Material and methods:
A case-control study was conducted in three centres in the Czech Republic (Olomouc, Ostrava, and České Budějovice) in 2006–2009. In total, 226 women (129 pancreas cancer cases, 97 controls) were included in the study. Statistical analysis was performed, the crude odds ratio (OR) was calculated, and logistic regression analysis was used at a 5% level of statistical significance.
Results:
A statistically significant inverse association was found between pancreatic cancer and oral contraceptives (OR 0.21; 95% CI: 0.07–0.69). Pregnancy and number of pregnancies or gynecological surgical procedures did not show any association with pancreatic cancer. No significant difference in the first menstrual period was found between pancreatic cancer patients and controls.
Conclusions:
The study results showed inverse association between pancreatic cancer and oral contraceptives (OR 0.21; 95% CI: 0.07–0.69), controlled alcohol consumption (OR 0.26; 95% CI: 0.12–0.55), and anti-inflamatory drug use (OR 0.10; 95% CI: 0.02–0.41).
Keywords:
pancreatic cancer – risk factor – multifactor analysis – odds ratio
Sources
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [on line]. Lyon, France: International Agency for Research on Cancer;2013. Dostupný na www: http://globocan.iarc.fr, accessed on 27/3/2014.
2. Dušek L, Mužík J, Kubásek M, Koptíková J et al. Epidemiologie zhoubných nádorů v České republice [on line]. Masarykova univerzita, [2005], [cit. 2014-3-27]. Dostupný na www: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802–8861.
3. Kollárová H, Janoutová G, Foretova L, Martínek A, Shonová O, Procházka V, Horáková D, Čížek L, Janout V. Epidemiologie karcinomu pankreatu [Pancreas cancer epidemiology]. Epidemiol Mikrobiol Imunol, 2007;56(1):38–43.
4. Ben Q, Xu M, Ning X, Liu J et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer, 2011;47(13):1928–1937.
5. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol, 2013;107(1):1–7.
6. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D et al. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol, 2012;27, (2):127–134.
7. Lee E, Horn-Ross PL, Rull RP, Neuhausen SL et al. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am J Epidemiol, 2013;178(9):1403–1413.
8. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog, 2012;51(1):53–63.
9. Urayama KY, Holcatova I, Janout V, Foretova L et al. Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. Int J Cancer, 2011;129(12):2875–1284.
10. Olson SH. Selected medical conditions and risk of pancreatic cancer. Mol Carcinog, 2012;51(1):75–97.
11. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D et al. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol, 2012; Suppl 2:127–134.
12. Li D, Morris JS, Liu J, Hassan MM et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA, 2009;301(24):2553–2562.
13. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta, 2013;1831(10):1499–1508.
14. Genkinger JM, Spiegelman D, Anderson KE, Bernstein L et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer, 2011;129(7):1708–1717.
15. Sovinová H, Csemy L, Warren CW, Lee J, Lea V. Changes in tobacco use among 13-15-year-olds in the Czech Republic--2002 and 2007. Cent Eur J Public Health, 2008;16(4):199–204.
16. Hsu C, Saif MW. Diabetes and pancreatic cancer. Highlights from the „2011 ASCO Annual Meeting“. Chicago, IL, USA; June 3-7, 2011. JOP, 2011;12(4):330–333.
17. DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol, 1999;10(Suppl 4):140–142.
18. Permert J, Larsson J, Westermark GT, Herrington MK et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med, 1994;330(5):313–318.
19. Schwarts SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein AH. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis, 1978;23(12):1107–1114.
20. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol, 2009;10(1):88–95.
21. Tsirambidis JV, Conwell DL, Zuccaro G. Chronic pancreatitis. Med Gen Med, 2003;5(1):17.
22. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med, 1993;328(20):1433–1437.
23. Kollárová H, Azeem K, Tomášková H, Procházka V et al. Zdravotní stav a karcinom pankreatu. Gastroent Hepatol, 2013;67(2):154–161.
24. Pastucha D, Horáková D, Janoutová G, Malinciková J, Janout V. Epidemiology of the metabolic syndrome and possibility for its prevention by physical activities. Epidemiol Mikrobiol Imunol, 2007;56(4):181–185.
25. Schernhammer ES, Kang JH, Chan AT, Michaud DS et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst, 2004;96(1):22–28.
26. Bradley MC, Hughes CM, Cantwell MM, Napolitano G et al. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer, 2010;102(9):1415–1421.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2015 Issue 1
Most read in this issue
- Macrolide resistance in Treponema pallidum subsp. pallidum in the Czech Republic and in other countries
- Contribution of the detection of IgA antibodies to the laboratory diagnosis of mumps in the population with a high vaccination coverage
- A case of tuberculous meningitis associated with persistently reduced CD4+ T lymphocyte counts
- Minimum inhibitory concentrations of erythromycin and other antibiotics for Czech strains of Bordetella pertussis